Aurinia Pharmaceuticals (AUPH) Price & Analysis

Compare

2,076 Followers

AUPH Stock Chart & Stats

Day’s Range― - ―

52-Week Range$6.42 - $12.53

Previous CloseN/A

Volume460.34K

Average Volume (3M)2.42M

Market Cap

$1.61B

Enterprise Value$931.54M

Total Cash (Recent Filing)$315.13M

Total Debt (Recent Filing)$81.83M

Price to Earnings (P/E)28.6

Beta0.75

Next Earnings

Oct 30, 2025

EPS Estimate

0.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.16

Shares Outstanding131,629,550

10 Day Avg. Volume1,935,627

30 Day Avg. Volume2,419,982

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.58

Enterprise Value/Revenue3.58

Enterprise Value/Gross Profit4.00

Enterprise Value/Ebitda10.77

Forecast

1Y Price Target

$12.00

Price Target Upside-0.91% Downside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

EarningsAurinia reported Lupkynis net product sales of $66.6M for the second quarter, above consensus estimates.

Financial PerformanceAurinia remains cash flow positive and ended the quarter with cash, cash equivalents, restricted cash, and investments of $315.1M.

Product DevelopmentAritinercept development is on track with plans to initiate clinical studies, indicating progress in their pipeline for autoimmune diseases.

Bears Say

Market StrategyThere is disappointment that Aurinia will remain standalone, as more value could have been created with strategic synergies in a more established commercial organization.

Sales ForecastThere is an expectation of modest erosion in sales in the third quarter due to typical seasonality.

Aurinia Pharmaceuticals News

Aurinia Pharmaceuticals raises 2025 revenue view to $260M-$270M from $250M-$260M

06:10 EDT Aurinia Pharmaceuticals (AUPH) raises 2025 revenue view to $260M-$270M from $250M-$260M Published first on TheFly –...

29d ago

AUPH

Aurinia Pharmaceuticals reports Q2 EPS 16c, consensus 15c

Reports Q2 revenue $70.0M, consensus $63.8M. As of June 30, 2025, Aurinia had cash, cash equivalents, restricted cash...

29d ago

AUPH

Aurinia Pharmaceuticals assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Arthur He assumed coverage of Aurinia Pharmaceuticals (AUPH) with a Buy rating and $17 price...

30d ago

AUPH

Aurinia Pharmaceuticals: Strong Financial Performance and Promising Pipeline Drive Buy Rating

Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on AUPH stock, giving a Buy rating on...

25d ago

AUPH

Aurinia Pharmaceuticals: Strong Financial Performance and Promising Future Justify Buy Rating

In a report released on August 1, David Martin PhD from Bloom Burton maintained a Buy rating on...

26d ago

AUPH

Aurinia Pharmaceuticals’ Earnings Call: Strong Growth and Optimism

Aurinia Pharmaceuticals (($AUPH)) has held its Q2 earnings call. Read on for the main highlights of the call....

27d ago

AUPH

Aurinia Pharmaceuticals Reports Strong Revenue Growth

Aurinia Pharmaceuticals ( ($AUPH) ) has released its Q2 earnings. Here is a breakdown of the information Aurinia...

28d ago

AUPH

Optimistic Buy Rating for Lupkynis Driven by Strong Sales and Promising Clinical Developments

Aurinia Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stacy Ku from...

28d ago

AUPH

Aurinia Pharmaceuticals Reports Strong Revenue Growth and Expands Share Repurchase Plan

Aurinia Pharmaceuticals ( ($AUPH) ) has provided an announcement. Aurinia Pharmaceuticals reported a significant increase in revenue for...

29d ago

AUPH

Aurinia Pharmaceuticals Reports Strong Q2 2025 Financial Results and Expands Share Repurchase Plan

Aurinia Pharmaceuticals ( ($AUPH) ) just unveiled an announcement. Aurinia Pharmaceuticals announced its financial results for the quarter...

29d ago

AUPH

Aurinia Pharmaceuticals to Announce Q2 2025 Financial Results

Aurinia Pharmaceuticals ( ($AUPH) ) just unveiled an announcement. Aurinia Pharmaceuticals announced it will release its second quarter...

1M ago

AUPH

Aurinia Pharmaceuticals Reports Positive Phase 1 Results for Aritinercept

Aurinia Pharmaceuticals ( ($AUPH) ) has issued an announcement. Aurinia Pharmaceuticals announced positive results from a Phase 1...

2M ago

AUPH

Aurinia Pharma reports ‘positive’ results from Phase 1 study of aritinercept

Aurinia Pharmaceuticals (AUPH) announced positive results from a Phase 1 single-ascending-dose study of aritinercept, its dual inhibitor of...

2M ago

AUPH

Aurinia Pharmaceuticals to Discuss AUR200 Phase 1 Study Results

Aurinia Pharmaceuticals ( ($AUPH) ) just unveiled an update. Aurinia Pharmaceuticals announced it will host a webcast and...

2M ago

AUPH

AUPH FAQ

What was Aurinia Pharmaceuticals’s price range in the past 12 months?

Aurinia Pharmaceuticals lowest stock price was $6.42 and its highest was $12.53 in the past 12 months.

What is Aurinia Pharmaceuticals’s market cap?

Aurinia Pharmaceuticals’s market cap is $1.61B.

When is Aurinia Pharmaceuticals’s upcoming earnings report date?

Aurinia Pharmaceuticals’s upcoming earnings report date is Oct 30, 2025 which is in 62 days.

How were Aurinia Pharmaceuticals’s earnings last quarter?

Aurinia Pharmaceuticals released its earnings results on Jul 31, 2025. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.147 by $0.013.

Is Aurinia Pharmaceuticals overvalued?

According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Aurinia Pharmaceuticals pay dividends?

Aurinia Pharmaceuticals does not currently pay dividends.

What is Aurinia Pharmaceuticals’s EPS estimate?

Aurinia Pharmaceuticals’s EPS estimate is 0.16.

How many shares outstanding does Aurinia Pharmaceuticals have?

Aurinia Pharmaceuticals has 131,629,550 shares outstanding.

What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?

Aurinia Pharmaceuticals reported an EPS of $0.16 in its last earnings report, beating expectations of $0.147. Following the earnings report the stock price went up 2.099%.

Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?

Currently, no hedge funds are holding shares in AUPH

Aurinia Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

17.33%

Trailing 12-Months

Asset Growth

-4.00%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Aurinia Pharmaceuticals (AUPH) Earnings & Revenues

Historic Earnings Reports

AUPH Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Aurinia Pharmaceuticals reported strong financial performance with significant revenue and net product sales growth, improved cash flow, increased guidance, and successful clinical trial results. However, there were decreases in cash, cash equivalents, and investments due to share repurchases.View all AUPH earnings summaries

AUPH Revenue Breakdown

90.00% U.S.

10.00% Japan

AUPH Stock 12 Month Forecast

Average Price Target

$12.00

▼(-0.91% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","11":"$11","18":"$18","7.5":"$7.5","14.5":"$14.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,7.5,11,14.5,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.49,10.990769230769232,11.491538461538461,11.992307692307692,12.493076923076924,12.993846153846153,13.494615384615384,13.995384615384616,14.496153846153845,14.996923076923077,15.497692307692308,15.998461538461537,16.49923076923077,{"y":17,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.49,10.606153846153846,10.722307692307693,10.838461538461539,10.954615384615385,11.070769230769232,11.186923076923076,11.303076923076922,11.419230769230769,11.535384615384615,11.651538461538461,11.767692307692307,11.883846153846154,{"y":12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.49,10.375384615384615,10.260769230769231,10.146153846153846,10.031538461538462,9.916923076923077,9.802307692307693,9.687692307692307,9.573076923076924,9.458461538461538,9.343846153846155,9.22923076923077,9.114615384615384,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.2,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.81,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.98,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.96,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.48,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.49,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >